{"product_id":"lnth-swot-analysis","title":"(LNTH) Lantheus Holdings, Inc. SWOT Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValidate Every Claim with the Complete Sources File\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Lantheus Holdings, Inc. SWOT Analysis provides a concise, company-specific breakdown of strengths, weaknesses, opportunities, and threats to support research, strategy, or investment decisions; the page already includes a real preview\/sample of the analysis so you can review style and substance before buying. Purchase the full version to download the complete, ready-to-use SWOT report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStrengths\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e10 diagnostic products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLantheus Holdings, Inc. sells 10 diagnostic products across ultrasound contrast, nuclear medicine, and PET, so it is not tied to one asset or one workflow. That breadth supports use in hospitals, clinics, and radiopharmacies, while PYLARIFY and DEFINITY anchor reach across major imaging channels. A wider portfolio also helps reduce product-specific demand swings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePYLARIFY in prostate cancer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePYLARIFY is a leading PSMA PET imaging agent for recurrent or metastatic prostate cancer, a market tied to the 1 in 8 lifetime risk of prostate cancer in men. Its ability to detect bone, lymph node, and soft tissue metastases gives Lantheus a strong edge in precision diagnostics and in one of oncology’s largest imaging opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished since 1956\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFounded in 1956, Lantheus Holdings, Inc. brings nearly 70 years of operating history as of July 2026. That long run supports physician trust, deeper manufacturing know-how, and stronger regulatory discipline across imaging and radiopharmaceutical products. It also shows the Company has stayed resilient through multiple healthcare, pricing, and reimbursement cycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003e2 therapeutic products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAZEDRA and RELISTOR give Lantheus Holdings, Inc. 2 marketed therapeutic products beyond diagnostics, which helps balance a business that still leans on imaging. In FY2025, that broader mix can add recurring sales, longer product lifecycles, and closer ties with specialists treating complex cancer and GI disease. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003e2 therapies broaden revenue sources\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eLess reliance on diagnostics only\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eSupports specialist relationships\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003e10 strategic partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLantheus Holdings, Inc. has 10 strategic partners, including NanoMab, Bausch Health, GE Healthcare, Curium, Bayer, CytoDyn, ROTOP, FUJIFILM, Regeneron, and POINT Biopharma. These alliances widen access to technology, manufacturing, and commercialization channels, which helps the Company move faster across multiple programs. Spreading development work across 10 partners also lowers single-program risk and supports a broader pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003e10 strategic partners expand reach\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eShared tech and manufacturing access\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eCommercialization support across markets\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eRisk spread across multiple programs\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLantheus’ Broad Imaging Mix Powers Oncology Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLantheus Holdings, Inc. strength comes from its broad imaging mix: 10 products across ultrasound contrast, nuclear medicine, and PET. PYLARIFY is a leading PSMA PET agent, giving the Company a strong oncology foothold. Two marketed therapies, AZEDRA and RELISTOR, also reduce reliance on imaging alone. Ten strategic partners support reach, tech, and manufacturing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProducts\u003c\/td\u003e\n\u003ctd\u003e10\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTherapies\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategic partners\u003c\/td\u003e\n\u003ctd\u003e10\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear SWOT framework for analyzing Lantheus Holdings, Inc.’s business strategy\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eDelivers a quick SWOT snapshot for Lantheus Holdings, Inc. to simplify strategic decision-making and reduce analysis fatigue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary industry reports, FDA filings, company filings, and trusted benchmarks to speed due diligence and validate key Lantheus assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eWeaknesses\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh dependence on imaging markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLantheus’s revenue is still heavily tied to diagnostic imaging and radiopharmaceutical use, so procedure volumes matter a lot. If hospital capital spending tightens or imaging reimbursement weakens, growth can slow fast. In its latest reported year, the company still derived the vast majority of sales from imaging-related products, leaving it exposed to any drop in scan demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated prostate cancer exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePYLARIFY is Lantheus Holdings, Inc.’s core growth engine, and PYLARIFY AI also sits inside prostate cancer, so the Company is heavily tied to one indication and one imaging pathway. In 2024, PYLARIFY revenue was about $1.0 billion, a very large share of total Company sales. If prostate cancer imaging standards shift, a major slice of Lantheus Holdings, Inc.’s growth can move fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited therapeutic scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLantheus Holdings, Inc.’s therapeutic business is still tiny next to its imaging franchise, which drove most of its roughly $1.3 billion revenue base in FY2024. AZEDRA and RELISTOR have not reached the scale of leading imaging assets like DEFINITY, so diversification stays thin. That leaves earnings more exposed to a few diagnostic products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePipeline execution risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLantheus Holdings, Inc. faces real pipeline execution risk because flurpiridaz F 18, 1095, LMI 1195, PYLARIFY AI, and leronlimab all depend on clean clinical, regulatory, and launch results. Even one delay or weak readout can hit future growth, especially after 2024 revenue reached about $1.4 billion and PYLARIFY remained the main cash engine. That makes pipeline misses a direct threat to the next leg of sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eFive programs need successful execution.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eAny delay can slow growth.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eNegative data can cut expected value.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eComplex radiopharmaceutical supply chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLantheus Holdings, Inc. relies on a tightly controlled radiopharmaceutical chain for TechneLite, Gallium-67, Thallium-201, and other products. Unlike small-molecule drugs, isotopes need specialized production, time-sensitive transport, and strict handling, so even a short outage can hit supply and trust.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialized isotope manufacturing raises failure risk.\u003c\/li\u003e\n\u003cli\u003eTransport delays can cut usable product life.\u003c\/li\u003e\n\u003cli\u003eSupply hits can reduce customer confidence fast.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePYLARIFY Dependence Leaves Lantheus Exposed\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLantheus Holdings, Inc.’s main weakness is concentration: PYLARIFY brought in about $1.0 billion of 2024 revenue, or most of Company sales, so one prostate imaging asset drives results. The rest of the portfolio is much smaller, and pipeline bets still face clinical and launch risk. Its isotope supply chain also adds outage risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eWeakness\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue mix\u003c\/td\u003e\n\u003ctd\u003e~$1.4B FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePYLARIFY\u003c\/td\u003e\n\u003ctd\u003e~$1.0B FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiversification\u003c\/td\u003e\n\u003ctd\u003eThin beyond imaging\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eLantheus Holdings, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis preview reflects the real SWOT analysis document you'll receive upon purchase—professional, structured, and ready to use. The excerpt below is taken directly from the full Lantheus Holdings, Inc. report; buy now to unlock the complete, editable version with comprehensive strengths, weaknesses, opportunities, threats, and strategic implications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eOpportunities\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePSMA PET expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePSMA PET keeps expanding as prostate cancer imaging gains wider use, and PYLARIFY is the main driver for Lantheus Holdings, Inc.; in 2024, PYLARIFY generated about $811 million in sales. More site adoption, smoother workflows, and broader clinical use can lift scan volume and repeat testing. That should widen patient access and keep utilization rising over time.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFlurpiridaz F 18 launch potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFlurpiridaz F 18, FDA-approved in 2024 as Flyrcado for PET myocardial perfusion imaging, gives Lantheus a higher-value tool for assessing myocardial blood flow in coronary artery disease. With U.S. CAD affecting about 20 million adults, even modest uptake can expand the cardiac imaging franchise and add a premium diagnostic revenue stream. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI software monetization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePYLARIFY AI can turn PSMA PET\/CT scans into standardized quantitative outputs, which helps doctors compare results faster and more consistently. Because software scales with far lower marginal delivery cost than radiopharmaceutical doses, Lantheus Holdings, Inc. can add recurring digital revenue without the same supply-chain burden. That also deepens workflow lock-in around the PYLARIFY platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNeuroblastoma asset LMI 1195\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLMI 1195 could give Lantheus entry into neuroblastoma, a rare cancer with about 700 to 800 new U.S. cases a year and roughly 15% of pediatric cancer deaths. If development succeeds, it would open a high-need oncology niche in children and adults, while also adding rare-disease and pediatric credibility. That matters because Lantheus is still anchored by imaging and needs new growth legs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRare, high-need oncology market\u003c\/li\u003e\n\u003cli\u003eTargets children and adults\u003c\/li\u003e\n\u003cli\u003eBoosts pediatric credibility\u003c\/li\u003e\n\u003cli\u003eExpands beyond core imaging\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnership-driven expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLantheus posted about $1.3 billion of 2024 revenue, and partnerships can help it scale PET imaging faster without building every capability in-house. Major healthcare and pharma partners can add manufacturing capacity, imaging expertise, and global commercialization reach, which can speed launches and limit capital spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFaster market reach through partner networks\u003c\/li\u003e\n\u003cli\u003eShared manufacturing and imaging expertise\u003c\/li\u003e\n\u003cli\u003eLower need for internal capex\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLantheus Growth: PYLARIFY Scale, Flyrcado Launch, and AI Upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLantheus Holdings, Inc. can grow by scaling PYLARIFY, which drove about $811 million of 2024 sales, and by pushing broader PSMA PET adoption. Flyrcado, approved in 2024, opens coronary imaging in a U.S. CAD market of about 20 million adults. PYLARIFY AI can add recurring software revenue, while LMI 1195 gives rare-disease upside. Partner deals can speed launches.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eOpportunity\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePYLARIFY\u003c\/td\u003e\n\u003ctd\u003e$811M sales, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFlyrcado\u003c\/td\u003e\n\u003ctd\u003eFDA-approved, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. CAD\u003c\/td\u003e\n\u003ctd\u003e~20M adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eThreats\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntense imaging competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntense imaging competition is a real threat for Lantheus Holdings, Inc. because GE Healthcare, Bayer, Curium, and FUJIFILM all have deep pockets and broad sales reach. In 2025, that kind of scale can push pricing lower, make contract wins harder, and squeeze market share. New imaging platforms can also reduce demand for legacy agents, so Lantheus has to keep proving clinical value fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory approval risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRadiopharmaceutical approvals are slow and strict, with FDA reviews often taking 10-12 months after filing and Phase 3 trials usually enrolling hundreds of patients. Lantheus Holdings, Inc.'s 1095 and LMI 1195 could face delays, safety flags, or manufacturing issues, pushing launch plans back by years. Any non-approval would hit future sales growth and lower the pipeline's value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eReimbursement pressure is a real threat for Lantheus Holdings, Inc. because PYLARIFY and other imaging tools depend on payer coverage and fair payment. If coverage tightens or rates fall, use can slow fast, especially in high-cost specialty diagnostics. In 2025, that risk matters more as payers keep pushing for lower spending and stricter prior authorization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSupply chain and isotope disruption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLantheus Holdings, Inc. depends on tightly timed isotope supply, cold-chain handling, and specialist manufacturing. The key risk is that many radiopharmaceutical inputs, like Mo-99 with a 66-hour half-life, lose usable activity fast, so even a short plant or transport break can cut dose availability and sales.\u003c\/p\u003e\n\u003cp\u003eThat makes supply shocks more damaging than in standard pharma: one missed shipment can disrupt scans the same day. If an upstream reactor, processing site, or courier network slips, Lantheus Holdings, Inc. can face lost revenue, backorders, and weaker customer trust.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIsotope decay is time-sensitive\u003c\/li\u003e\n\u003cli\u003eFew qualified suppliers exist\u003c\/li\u003e\n\u003cli\u003eShort outages hit output fast\u003c\/li\u003e\n\u003cli\u003eLost doses can mean lost sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical adoption uncertainty\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical adoption is still a risk for Lantheus Holdings, Inc.: PYLARIFY brought in $908.2 million of revenue in 2024, but new tools like PYLARIFY AI and pipeline assets still need broad physician buy-in. If clinicians keep older workflows or rival standards, uptake can lag and cut the return on R\u0026amp;D spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePYLARIFY revenue: $908.2 million, 2024\u003c\/li\u003e\n\u003cli\u003eAdoption depends on physician workflow fit\u003c\/li\u003e\n\u003cli\u003eSlow uptake can depress R\u0026amp;D returns\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLantheus Faces Fierce Competition and Pipeline Delays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGE Healthcare, Bayer, Curium, and FUJIFILM keep pricing and share pressure high for Lantheus Holdings, Inc., while new imaging platforms can also reduce demand for older agents.\u003c\/p\u003e\n\u003cp\u003eRadiopharmaceutical approvals stay slow and strict, so 1095 and LMI 1195 face delay, safety, and manufacturing risk that can push launches back.\u003c\/p\u003e\n\u003cp\u003ePYLARIFY's $908.2 million 2024 revenue still depends on payer coverage, physician adoption, and time-sensitive isotope supply.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eThreat\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetition\u003c\/td\u003e\n\u003ctd\u003eGE Healthcare, Bayer, Curium, FUJIFILM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline risk\u003c\/td\u003e\n\u003ctd\u003e1095, LMI 1195\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial risk\u003c\/td\u003e\n\u003ctd\u003ePYLARIFY revenue: $908.2 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234671239433,"sku":"lnth-swot-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/lnth-swot-analysis.webp?v=1785724032","url":"https:\/\/dcfanalyst.com\/products\/lnth-swot-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}